 Connection
David Mathes to Immunotoxins
This is a "connection" page, showing publications David Mathes has written about Immunotoxins.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.818 |
|
|
|
-
Ma J, Wang Z, Mintzlaff D, Zhang H, Ramakrishna R, Davila E, Witkowski MT, Lucia MS, Schwartz MS, Pomfret EA, Mathes DW, Wang Z. Bivalent CD47 immunotoxin for targeted therapy of T-cell acute lymphoblastic leukemia. Blood. 2025 Jan 30; 145(5):508-519.
Score: 0.231
-
Wang Z, Ramakrishna R, Wang Y, Qiu Y, Ma J, Mintzlaff D, Zhang H, Li B, Hammell B, Lucia MS, Pomfret E, Su AA, Washington KM, Mathes DW, Wang Z. Toxicology, pharmacokinetics, and immunogenicity studies of CCR4-IL2 bispecific immunotoxin in rats and minipigs. Eur J Pharmacol. 2024 Apr 05; 968:176408.
Score: 0.216
-
Wang Z, Ma J, Zhang H, Ramakrishna R, Mintzlaff D, Mathes DW, Pomfret EA, Lucia MS, Gao D, Haverkos BM, Wang Z. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model. FEBS Open Bio. 2023 07; 13(7):1309-1319.
Score: 0.205
-
Wang H, Wang Z, Zhang H, Qi Z, Johnson AC, Mathes D, Pomfret EA, Rubin E, Huang CA, Wang Z. Bispecific human IL2-CCR4 immunotoxin targets human cutaneous T-cell lymphoma. Mol Oncol. 2020 05; 14(5):991-1000.
Score: 0.165
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|